Cargando…

Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?

Detalles Bibliográficos
Autor principal:	Jeong, Soung Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160348/ https://www.ncbi.nlm.nih.gov/pubmed/32192273 http://dx.doi.org/10.3350/cmh.2020.0046

Ejemplares similares

Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis
por: Rivera, Chantal A, et al.
Publicado: (2010)

Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management
por: Salomone, Federico, et al.
Publicado: (2015)

Innate Lymphoid Cells: New Culprits of Alcohol-Associated Steatohepatitis
por: Choi, Sung Eun, et al.
Publicado: (2022)

Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease
por: Baumann, Anja, et al.
Publicado: (2021)

Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
por: Shiina, Shuichiro, et al.
Publicado: (2023)

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
por: Yoshiji, Hitoshi, et al.
Publicado: (2009)

Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis?
por: Eun, Hyuk Soo
Publicado: (2020)

Exercise Alleviates the Apolipoprotein A5-Toll-Like Receptor 4 Axis Impairment in Mice With High-Fat Diet-Induced Non-alcoholic Steatohepatitis
por: Yu, Yang, et al.
Publicado: (2021)

Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis
por: Nguyen, Jennifer, et al.
Publicado: (2018)

Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2020)

Toll-Like Receptor Signaling in Liver Diseases
por: Szabo, Gyongyi, et al.
Publicado: (2010)

A New Rodent Model of Non-Alcoholic Steatohepatitis and Metabolic Syndrome
por: Romeiro, Fernando Gomes, et al.
Publicado: (2019)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Toll-Like Receptor 9 in Breast Cancer
por: Sandholm, Jouko, et al.
Publicado: (2014)

Toll-Like Receptors in the Pathogenesis of Alcoholic Liver Disease
por: Petrasek, Jan, et al.
Publicado: (2010)

Toll-like receptor 2: therapeutic target for gastric carcinogenesis
por: McCormack, William, et al.
Publicado: (2012)

Toll-like receptor 4 in COVID-19: friend or foe?
por: Mukherjee, Suprabhat
Publicado: (2022)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Liver stiffness measurement: Is it a non-invasive substitution for HVPG?
por: Jeong, Soung Won
Publicado: (2013)

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States
por: Eeckhoute, Jérôme
Publicado: (2022)

Modulation of Toll-Like Receptor Signalling as a New Therapeutic Principle
por: Lepper, Philipp M., et al.
Publicado: (2010)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
por: Armstrong, Matthew J., et al.
Publicado: (2016)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Toll-like receptor 7 affects the pathogenesis of non-alcoholic fatty liver disease
por: Kim, Sokho, et al.
Publicado: (2016)

Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?
por: Cao, Ying, et al.
Publicado: (2020)

The Significance of Toll-Like Receptors in the Neuroimmunologic Background of Alcohol Dependence
por: Czerwińska-Błaszczyk, Agnieszka, et al.
Publicado: (2022)

A new “sweet” ligand for Toll-like receptor 4
por: Deierborg, Tomas, et al.
Publicado: (2015)

Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatment
por: Seo, Seol Hwa, et al.
Publicado: (2022)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Fibroscan-AST (FAST) score and other non-invasive tests for the diagnosis of fibrotic non-alcoholic steatohepatitis
por: Chan, Wah Loong, et al.
Publicado: (2023)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Patents for Toll-like receptor ligands as radiation countermeasures for acute radiation syndrome
por: Singh, Vijay K, et al.
Publicado: (2015)

Emerging roles of Toll-like receptor 9 in cardiometabolic disorders
por: Nishimoto, Sachiko, et al.
Publicado: (2020)

Toll-Like Receptor 9 Mediated Responses in Cardiac Fibroblasts
por: Ohm, Ingrid Kristine, et al.
Publicado: (2014)

Human papillomavirus (HPV) deregulation of Toll-like receptor 9
por: Hasan, Uzma
Publicado: (2014)

Toll-like receptor 9 antagonizes antibody affinity maturation
por: Akkaya, Munir, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4igg7bnmrs8fto3lv3dspki2am